AZ1495 |
Catalog No.GC33054 |
AZ1495, una base débil, es un potente inhibidor de la quinasa 4 asociada al receptor de la interleucina-1 activo por vÍa oral (IRAK4). AZ1495 tiene una selectividad fisicoquÍmica y quinasa favorable para IRAK4 e IRAK1 con valores de CI50 de 0,005 μM y 0,023 μM, respectivamente. AZ1495 tiene una inhibiciÓn de IRAK4 con un valor de Kd de 0,0007 μM. AZ1495 se puede utilizar para la investigaciÓn del linfoma difuso de células B grandes (DLBCL).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2196204-23-4
Sample solution is provided at 25 µL, 10mM.
AZ1495 (compound 28) is an oral active inhibitor of Interleukin-1 receptor associated kinase 4 (IRAK4), with IC50 values of 5 nM and 23 nM for IRAK4 and IRAK1, respectively. Shows activity in treatment of mutant MYD88L265P diffuse large B-cell lymphoma (DLBCL)[1].
[1]. Scott JS, et al. Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma. J Med Chem. 2017 Dec 28;60(24):10071-10091.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *